The purpose of the study is to evaluate the predictive value of 18F-fluoromisonidazol-PET (FMISO-PET), 2-18F-fluoro-2-deoxy-d-glukose-PET-CT (FDG-PET-CT), Diffusion-Weighted Magnetic Resonance Imaging (DWI-MRI) and Dynamic Contrast-Enhanced Magnetic Resonance Imaging (DCE-MRI) for patients with anal cancer receiving radiation therapy +/- chemotherapy (Cisplatin and 5-FU).
The study involves tree MRI sessions, two FDG-PET-CT sessions and one FMISO-PET session. The FMISO-PET session is presently not carried out because of delivery problems. The production of 18F-fluoromisonidazol at The Department of Clinical Physiology and Nuclear Medicine, Copenhagen University Hospital Herlev, Denmark has not jet been approved by the Danish Medicines Agency.
Study Type
OBSERVATIONAL
Enrollment
50
This study involves 6 imaging sessions. One FMISO-PET before radiation therapy, one FDG-PET-CT before radiation therapy and one FDG-PET-CT during radiation therapy and tree Magnetic Resonance imaging (MRI) sessions with one session before radiation therapy, one session during radiation therapy and one sessions post radiation.
Department of Oncology Herlev Hospital
Herlev, Denmark
RECRUITINGTumor response
* Primary tumor 18-F-deoxyglucose (FDG) uptake before radiation and during week 3 of radiation. * Primary tumor apparent diffusion coefficient before radiation and during week 3 of radiation and 6-8 weeks post radiation * Primary tumor perfusion coefficient before radiation and during week 3 of radiation and 6-8 weeks post radiation * Primary tumor 18-F-Fluoromisonidazol (FMISO) uptake before radiation
Time frame: 6-8 weeks post radiation
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.